Literature DB >> 16980556

Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization.

Robert H Moore1, Ellen E Millman, Veronica Godines, Nicola A Hanania, Tuan M Tran, Hui Peng, Burton F Dickey, Brian J Knoll, Richard B Clark.   

Abstract

Salmeterol is a long-acting beta(2)-adrenergic receptor (beta(2)AR) agonist commonly used in the treatment of asthma and chronic obstructive pulmonary disease. It differs from other beta-agonists in that it has a very low intrinisic efficacy, especially when compared with the other available long-acting beta-agonist, formoterol. Receptor desensitization and down-regulation has been described with the chronic use of beta-agonists. This effect may not be the same with all beta-agonists and may be related to their stabilization of altered receptor states. The extreme hydrophobicity and high-affinity quasi-irreversible binding of salmeterol have rendered studies examining the mechanisms by which it mediates receptor desensitization, down-regulation, and internalization difficult. We determined the capacity of salmeterol to induce beta(2)AR endocytosis, G protein-coupled receptor kinase (GRK)-site phosphorylation, degradation, and beta-arrestin2 translocation in HEK293 cells as compared with other agonists of varying intrinsic efficacies. Despite stimulating GRK-mediated phosphorylation of Ser355,356 after 30 min and 18 h to an extent similar to that observed with agonists of high intrinsic efficacy, such as epinephrine and formoterol, salmeterol did not induce significant beta(2)AR internalization or degradation and was incapable of stimulating the translocation of enhanced green fluorescent protein-beta-arrestin2 chimera (EGFP-beta-arrestin2) to the cell surface. Salmeterol-induced receptor endocytosis was rescued, at least in part, by the overexpression of EGFP-beta-arrestin2. Our data indicate that salmeterol binding induces an active receptor state that is unable to recruit beta-arrestin or undergo significant endocytosis or degradation despite stimulating considerable GRK-site phosphorylation. Defects in these components of salmeterol-induced receptor desensitization may be important determinants of its sustained bronchodilation with chronic use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980556      PMCID: PMC1899312          DOI: 10.1165/rcmb.2006-0158OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  44 in total

1.  The stability of the agonist beta2-adrenergic receptor-Gs complex: evidence for agonist-specific states.

Authors:  A M Krumins; R Barber
Journal:  Mol Pharmacol       Date:  1997-07       Impact factor: 4.436

2.  beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists.

Authors:  B January; A Seibold; B Whaley; R W Hipkin; D Lin; A Schonbrunn; R Barber; R B Clark
Journal:  J Biol Chem       Date:  1997-09-19       Impact factor: 5.157

3.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

Authors:  R A Pauwels; C G Löfdahl; D S Postma; A E Tattersfield; P O'Byrne; P J Barnes; A Ullman
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

4.  Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor.

Authors:  A W Gagnon; L Kallal; J L Benovic
Journal:  J Biol Chem       Date:  1998-03-20       Impact factor: 5.157

Review 5.  The pharmacology of salmeterol.

Authors:  M Johnson; P R Butchers; R A Coleman; A T Nials; P Strong; M J Sumner; C J Vardey; C J Whelan
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

6.  Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization.

Authors:  S S Ferguson; W E Downey; A M Colapietro; L S Barak; L Ménard; M G Caron
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

7.  Rapid onset of tolerance to the bronchoprotective effect of salmeterol.

Authors:  R Bhagat; S Kalra; V A Swystun; D W Cockcroft
Journal:  Chest       Date:  1995-11       Impact factor: 9.410

8.  Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.

Authors:  K J Morrison; R H Moore; N D Carsrud; J Trial; E E Millman; M Tuvim; R B Clark; R Barber; B F Dickey; B J Knoll
Journal:  Mol Pharmacol       Date:  1996-09       Impact factor: 4.436

9.  Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor.

Authors:  S A Green; A P Spasoff; R A Coleman; M Johnson; S B Liggett
Journal:  J Biol Chem       Date:  1996-09-27       Impact factor: 5.157

10.  Human lung cell beta 2-adrenergic receptors desensitize in response to in vivo administered beta-agonist.

Authors:  J Turki; S A Green; K B Newman; M A Meyers; S B Liggett
Journal:  Am J Physiol       Date:  1995-11
View more
  28 in total

Review 1.  Regulation of β-adrenergic receptor function: an emphasis on receptor resensitization.

Authors:  Neelakantan T Vasudevan; Maradumane L Mohan; Shyamal K Goswami; Sathyamangla V Naga Prasad
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

Review 2.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 3.  β-Arrestins 1 and 2 are critical regulators of inflammation.

Authors:  Hongkuan Fan
Journal:  Innate Immun       Date:  2013-09-12       Impact factor: 2.680

Review 4.  Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma.

Authors:  Raymond B Penn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-16       Impact factor: 3.000

Review 5.  Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.

Authors:  Steven J Charlton
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

Review 6.  Barcoding of GPCR trafficking and signaling through the various trafficking roadmaps by compartmentalized signaling networks.

Authors:  Suleiman W Bahouth; Mohammed M Nooh
Journal:  Cell Signal       Date:  2017-04-24       Impact factor: 4.315

Review 7.  Airway smooth muscle in the pathophysiology and treatment of asthma.

Authors:  Diana C Doeing; Julian Solway
Journal:  J Appl Physiol (1985)       Date:  2013-01-10

8.  Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of β2-Adrenergic Receptors.

Authors:  Luis E Gimenez; Faiza Baameur; Sharat J Vayttaden; Richard B Clark
Journal:  Mol Pharmacol       Date:  2015-03-17       Impact factor: 4.436

9.  Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the β2-adrenoceptor.

Authors:  Michael T Reinartz; Solveig Kälble; Timo Littmann; Takeaki Ozawa; Stefan Dove; Volkhard Kaever; Irving W Wainer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-24       Impact factor: 3.000

10.  Quantitative modeling of GRK-mediated beta2AR regulation.

Authors:  Sharat J Vayttaden; Jacqueline Friedman; Tuan M Tran; Thomas C Rich; Carmen W Dessauer; Richard B Clark
Journal:  PLoS Comput Biol       Date:  2010-01-22       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.